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46 cases in which the diagnosis was determined with only cytology, 9 
cases were different in diagnosis between cytology and pathology. Sev-
en cases were different only in cell typing of primary lung cancer. One 
case diagnosed as primary lung cancer by cytology was diagnosed as 
metastatic lung cancer from colon cancer by pathology. The other case 
diagnosed as metastatic lung cancer from breast cancer was diagnosed 
as primary lung cancer by pathology. There were no false positive cases 
regarding malignancy.
Conclusion: These results suggest that intra-operative FNA cytology 
with the modiﬁed Shorr’s staining method is useful for diagnosing 
malignancy-suspected pulmonary nodules in clinical practice.
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Introduction: A few prospective studies concerning diagnosis and 
treatment of large cell neuroendocrine lung cancer were published, as 
this tumor seems relatively rare. The objectives of GFPC 03-02 pro-
spective study were to establish the efﬁciency of Cisplatinum /Etopo-
side chemotherapy and to valid value of large spectrum cytokeratins in 
the diagnosis of neuro-endocrine differnciation.
Methods: Patients with stage IV and stage III B (with neoplasic pleural 
effusion) were included; treatment consisted in three cycles of Cisplati-
num 80mg/m2 d1 / Etoposide 100mg/m2 d1d2d3 and two more cycles 
in case of objective response or stable disease.
The primary objective is the efﬁciency of this chemotherapy, second-
ary objective the validation of the paranuclear granular expression of 
a large spectrum cytokeratin, as a characteristic of neuro-endocrine 
differentiation. Slides were controlled by a panel of pathologists. Diag-
noses were based on Travis’s criterias.
Results: 27 patients were included since May 2004. The slides of 21 
cases were reviewed. 14 cases were conﬁrmed as LCNEC. 4 were 
excluded on the basis of the nuclear criteria or cell size, and classiﬁed 
as small-cell carcinomas (SCC). One was excluded, because immuno-
histochemistry was not available. Two other patients were excluded be-
cause of the misinterpretation of the pathologic report by the clinicians 
(one SCC, one Large cell Carcinoma).
Among the 14 cases, two sub-types were observed:
- 8 LCNEC with neuroendocrine features and positive immunohisto-
chemistry
- 6 undifferentiated carcinomas with immunohistochemical neuroen-
docrine differentiation.
None case was diagnosed as large-cell carcinoma with neuroendocrine 
pattern and negative immunohistochemistry.
Table 1. Immunohistochemical results
Antibodies Positive Negative Not Evaluated
Cytokeratin (AE1/AE3 or KL1 or MNF116) 5 2 7
Chromogranin A 12 0 2
Synaptophysin 12 0 2
CD56 6 3 5
TTF1 7 2 5
In all cases, at least two of the three neuroendocrine markers (chromo-
granin A, synaptophysin, CD56) were positive.
Discussion: Interobserver variability is not observed on the criterias 
of neuroendocrine immunohistochemical differentiaton, but only on 
the criterias of size. Some small scratched samples led to difﬁculties to 
distinguish small-cell carcinoma from large-cell carcinoma, especially 
when neuroendocrine morphology (rosettes, trabecular growth pat-
tern,…) was not present. It seems necessary to deﬁnite how many of 
the Travis’s criterias are necessary to accept the diagnosis of LCNEC 
(cell size, chromatin, nucleoli, nuclear-to-cytoplasmic ratio, large and 
eosinophilic or granular cytoplasm) when neuroendocrine differen-
tiation is proved. This interobserver variability is described in the 
literature (1).
Value of the paranuclear granular expression with Cytokeratins must be 
evaluated on cases not yet tested.
Conclusion: Panel of pathologists is useful to diagnose LCNEC. Dis-
agrements were on cell size, some LCNEC were reclassiﬁed as SCC. 
Usefulness of cytokeratins needs some more patients tested.
(1) W.D.Travis, A.A. Gal, T.V. Colby and coll. Reproductibility of neu-
roendocrine lung tumor classiﬁcation. Hum Pathol 1998, 29: 272-279
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Stromal invasion of cancer is associated with proliferation of stromal 
myoﬁbroblasts. These cells are considered as activated ﬁbroblasts that 
facilitate invasion and metastasis of cancer cells. Myoﬁbroblasts in ear-
ly lung adenocarcinoma lesions, such as pure bronchiolo-alveolar carci-
noma (BAC) and mixed type adenocarcinoma with a BAC component, 
are not well documented in the literature. We report here the presence 
of subepithelial myoﬁbroblasts in pure bronchiolo-alveolar carcinoma 
(BAC) and a subset of invasive lung adenocarcinomas. We also charac-
terized their immunohistochemical proﬁles, investigated their relation-
ships with stromal invasion and the prognostic signiﬁcance.
Materials and Methods: A total of 75 cases of surgically resected lung 
adenocarcinomas were examined. There were 9 cases of BAC, 14 cases 
of mixed type adenocarcinoma with a BAC component, and 52 cases 
of pure invasive adenocarcinomas. All cases were immunostained for 
smooth muscle α-actin to visualize myoﬁbroblasts. Selected cases were 
also stained for calponin, desmin and h-caldesmon. 
Results: In all cases of pure BACs, we could observe subepithelial 
myoﬁbroblasts. These cells were characterized by their peculiar loca-
tion between cancer cells and alveolar septa. Immunohistochemically, 
they were positive for smooth muscle α-actin and calponin. Some were 
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also positive for desmin and h-caldesmon, suggesting that a fraction 
of these cells have a smooth muscle-like phenotype. In mixed adeno-
carcinoma with a BAC component, subepithelial myoﬁbroblasts were 
present in the BAC componenet, but there seemed to be a gradual loss 
of a typical subepithelial pattern of myoﬁbroblasts in invasive areas; 
they either disappeared partially or formed concentric layers of myo-
ﬁbroblasts around cancer cell nests. In most cases of frankly invasive 
adenocarcinoma, subepithelial myoﬁbroblasts were absent and bundles 
of myoﬁbroblasts emerged in cancer stroma. To further characterize the 
relationship to stromal invasion, we immmunostained adjacent sections 
for laminin-1 and collagen type 4 to highlight basement membranes, 
and then compared the results with smooth muscle α-actin staining. As 
expected, stromal invasion was associated with disruption of basement 
membranes and loss of a typical subepithelial pattern of myoﬁbroblasts. 
Interestingly, however, a subset of invasive adenocarcinomas partially 
retained subepithelial myoﬁbroblast, and survival analysis showed that 
invasive tumors with partial retention of subepithelial myoﬁbroblasts 
were associated with low rates of lymphatic and vascular invasion, 
lymph node involvement, and better patient survival. 
Conclusions: The results of this study suggest that subepithelial 
myoﬁbroblasts occur in bronchiolo-alveolar carcinomas, but they were 
gradually replaced by typical stromal myoﬁbroblasts during progres-
sion into invasive cancer. A subset of invasive adenocarcinomas retains 
subepithelial myoﬁbroblasts. Analysis of subepithelial myoﬁbroblasts 
may be helpful in deﬁning a subset of lung adenocarcinoma with good 
prognosis. 
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Background: Several researchers have reported the efﬁcacy of ad-
juvant chemotherapy in resected stage IB non-small cell lung cancer 
(NSCLC) patients. Due to the considerable variation in histological 
ﬁndings and outcomes of stage IB lung adenocarcinoma, it appeared 
there were unidentiﬁed subgroup factors. These factors affect treatment 
recommendations and choices. Identifying patients who do not need 
adjuvant chemotherapy saves patient stress and medical resources. This 
study’s aim was to investigate resected stage IB adenocarcinoma pa-
tient prognostic factors and identify a subgroup with a better outcome, 
where adjuvant chemotherapy might not be beneﬁcial and needed.
Methods: We reviewed records of 413 consecutive stage I lung 
adenocarcinoma patients who underwent complete surgical resection 
and systematic lymph node dissection at the National Cancer Center 
Hospital East from July 1992 through March 2000, to ﬁnd 106 stage IB 
patients for prognostic factor investigation. We evaluated four clinical 
factors: gender, age (<70 vs. ≥70 years), smoking history (positive vs. 
negative), and serum carcinoembryonic antigen (CEA) level (<5 vs. ≥5 
ng/ml). Seven pathological factors were also evaluated: maximum tu-
mor diameter (<5 vs. ≥5 cm), differentiation grade (well vs. moderately 
or poorly differentiated), lymphatic permeation (positive vs. negative), 
vascular invasion (positive vs. negative), pleural invasion (positive 
vs. negative), and bronchioloalveolar carcinoma (BAC) component 
dominance (positive vs. negative). BAC component dominance was 
considered positive if the histological evaluation found half or more of 
the tumor consisted of a BAC component. A subgroup with better out-
comes was identiﬁed and their survival compared with that of all stage 
IA patients who underwent surgical resection during the same period.
Results: The 5-year survival rate of all the stage IB lung adenocar-
cinoma patients was 81.7%. Univariate analyses found lymphatic 
permeation (p<0.001), vascular invasion (p=0.003), pleural invasion 
(p=0.001) and BAC-dominant histology (p=0.003) were signiﬁcant 
unfavorable prognostic factors. A multivariate analysis demonstrated 
positive pleural invasion (p=0.02) was an independent unfavorable 
prognostic factor. The stage IB lung adenocarcinoma patients 5-year 
survival rate with and without pleural invasion of 63% and 89%, 
respectively shows the invasion factor impact. Additionally, stage IB 
adenocarcinoma patients without pleural invasion overall survival rate 
was very similar to that of stage IA patients (92.7%; p=0.78). 
Conclusions: Pleural invasion is a factor that should be considered 
before recommending adjuvant chemotherapy to stage IB lung adeno-
carcinoma patients. The outcome for stage IB lung adenocarcinoma 
patients without pleural invasion is almost identical to stage IA patients 
where adjuvant chemotherapy has not shown an advantage. Adjuvant 
chemotherapy probably is not necessary or beneﬁcial for stage IB 
patients without pleural invasion.
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The presence of epidermal growth factor receptor (EGFR) tyrosine 
kinase (TK) mutations signiﬁcantly correlates with tumor sensitivity to 
tyrosine kinase inhibitor. Importantly, this mutation underlies respon-
siveness of the most predominant histologic subtype, adenocarcinoma. 
To clarify the correlation with EGFR mutations and pathological 
ﬁndings of adenocarcinomas of Japanese patients, detailed patho-
logical features of the tumor were examined. Total of 107 surgically 
resected adenocarcinomas were investigated. Seventeen cases treated 
with geﬁtinib for relapse were included. We reviewed medical records, 
pathology slides and examined EGFR mutations in exon 18-21. EGFR 
mutations were found in sixty ﬁve (60.7%) patients and detected in 
all four exons. EGFR mutations were signiﬁcantly associated with 
female gender (P<0.01), non-smoker status (P<0.05), hobnail cell type 
dominancy (P<0.0001), and papillary subtype (<0.0001). In addition, 
detailed pathological examination represented that the existence of 
bronchioloalveolar carcinoma (BAC) and micropapillary pattern (MPP) 
component was signiﬁcantly associated with EGFR mutations (P<0.05 
and <0.05, respectively). In seventeen patients with geﬁtinib treatment, 
